DALLAS / Aug 15, 2024 / Business Wire / Tenet Healthcare Corporation (NYSE: THC) is scheduled to present at the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, beginning at 9:30 a.m. Eastern time.
A live webcast and audio archive of the event may be accessed through the investor relations section of Tenet’s website at www.tenethealth.com/investors. The replay will be available for 30 days.
About Tenet Healthcare
Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates ambulatory surgery centers and surgical hospitals. We also operate a national portfolio of acute care and specialty hospitals, other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com.
Last Trade: | US$128.74 |
Daily Change: | -0.97 -0.75 |
Daily Volume: | 10,090 |
Market Cap: | US$12.240B |
October 29, 2024 July 24, 2024 April 30, 2024 February 08, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB